|Articles|January 1, 1996

January 1996
Volume 2
Issue 1

Modeling the Cost-Effectiveness of Oral Therapy for Nail Fungus

Author(s)Michael T. Halpern, MD, PhD, Cynthia Palmer, MSc

Download PDF: Modeling the Cost-Effectiveness of Oral Therapy for Nail Fungus

Articles in this issue

over 30 years ago

Article

Impact of Insurance Type on Receipt of Medical Care by HIV-Infected Men

over 30 years ago

Article

Aspirin After Myocardial Infarction: Patient Experience in a Managed Care Setting

over 30 years ago

Article

The Palliation of Cancer Patients -- Balancing Quality of Life, Cost, and Therapy

over 30 years ago

Article

Who Keeps the Gender Gate: Ethical and Policy Implications of OB-GYNs as Primary Caregivers

over 30 years ago

Article

The Use of Patient-Perceived Outcome Data in Today's Competitive Managed Care Environment: Suggestions for Providers and Managed Care Organizations

over 30 years ago

Article

Managed Care and HIV Disease

over 30 years ago

Article

Enhancing Skills in Clinical Resource Management: A Managed Care Approach

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Modeling the Cost-Effectiveness of Oral Therapy for Nail Fungus

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Modeling the Cost-Effectiveness of Oral Therapy for Nail Fungus

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care